Study Objectives: To investigate the frequency of microarousals (MA) associated with pressure changes during auto-CPAP therapy (APAP) for obstructive sleep apnea (OSA). Design: Patients with OSA were studied by polysomnography during APAP therapy (Somnosmart ® ). The MA were classified on the basis of concomitant changes in APAP pressure. Setting: Sleep laboratory of a university hospital Participants: 30 patients with moderate to severe OSA. Measurements and Results: The mean AHI during APAP was 4.7±4.7, the mean arousal index was 14.5±6.6 per hour. During epochs with a pressure variation greater than 0.5 mbar, significantly more MA occurred (0.30±0.17 MA per epoch) than in epochs with constant treatment pressure (0.10±0.054 MA per epoch; p<0.001). There were more MA during pressure-increase epochs than during pressure-decrease epochs (0.42±0.24 vs. 0.16±0.12 MA per epoch; p<0.001). 82.5 percent of the MA were not preceded by a significant change in pressure (at least 0.5 mbar within 30 sec.), 10.6% were associated with a significant prior increase and 6.9% with a significant prior decrease in pressure. The percentage of MA preceded by a significant pressure variation varied between 2.3% and 61%, with a mean of 18.9%. Conclusions: The overall frequency of MA was low, and in most individuals the relative amount of "pressure-associated MA" was not significant. However in some individuals it cannot be excluded that some additional MA may have been induced by pressure variations. Should it prove possible to prevent such "pressure-associated MA" by optimizing the regulation of APAP pressure, the overall clinical effect of APAP treatment may be improved.
INTRODUCTION

SINCE ITS INTRODUCTION BY SULLIVAN IN 1981, NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) THERAPY HAS BEEN THE STANDARD TREAT-
MENT FOR OBSTRUCTIVE SLEEP APNEA SYNDROME (OSA). 1, 2 The treatment pressure is selected to be high enough to avoid apneas, hypopneas, and snoring and thus, respiratory arousals, as completely as possible in all sleep stages and body positions. The minimal effective pressure (P eff ), necessary to counter the critical closing pressure (P crit ) of the upper airways is not a constant. Rather, it shows short-and long-lasting fluctuations, for example, as a result of changes in body position during sleep, and variations in sleep stage throughout the night. At the same time, there is a-sometimes pronounced-night-to-night variability in the P eff , due for example, to varying nasal obstruction; use of alcohol or sedatives; irregular sleeping habits; such as in shift workers; and in the long-term also as a result of changes in body weight. [3] [4] [5] [6] [7] Against this background, recent years have seen the development of auto-CPAP devices (APAP) that automatically and continually match treatment pressure to the actual momentary requirements of the patient. With these devices, the main aim is to achieve a reduction in the mean treatment pressure and to optimize therapeutic quality. 8, 9 As a result, APAP treatment may possibly be more comfortable for the patient and long-term compliance improved. The control parameters and the algorithms of the various auto-CPAP devices are largely different and the results obtained with one specific device cannot be easily transferred to other devices. Some older APAP devices failed to prove as effective as conventional CPAP treatment. [10] [11] [12] For some more advanced APAP devices it has repeatedly been shown that treatment with these devices is equally as effective as conventional CPAP treatment and that APAP treatment can indeed appreciably reduce the mean treatment pressure. 7, [13] [14] [15] [16] [17] Nevertheless even for highly developed APAP devices, it has not yet been demonstrated that treatment with an APAP device is significantly superior to conventional constant-pressure treatment in terms of therapeutic quality. 10, 13, 15, 16, 18 A theoretical reason for this is the possible induction of microarousals (MA) by the considerable number of automatic pressure variations during APAP treatment. Such a possibility has long been under discussion, but it still remains unclear whether a relevant proportion of MA actually occurs as a consequence of these pressure variations. Clarification of this point is certainly of clinical relevance, since, if MA do occur in significant numbers as a result of automatic pressure variations, an attempt could be made to optimize the control algorithm of the APAP device so as to avoid these MA and thus improve treatment quality. To date, however, no studies have been performed to systematically investigate this point.
For this study we choose the Somnosmart ® (Weinmann, Hamburg), an APAP device controlled by forced oscillation technique. The technical principles of this device have recently been discussed elsewhere. 15, 16, [19] [20] [21] [22] An analysis of individual MA, with the intention of clarifying this point is usually not particularly productive. If, for example, the APAP device increases treatment pressure in response to episodes of upper-airways obstruction and MA occur during this process, it cannot be reliably established whether these MA are a due to the upper airways obstruction or to the increase in pressure. Similar remarks apply in principle to the converse pressuredecrease situation. The MA occurring during such decreases in pressure may be triggered either by the decrease in pressure itself, or by the increased upper airways resistance resulting from the pressure decrease, and reliable differentiation of the MA genesis is again impossible.
An initial approximation of the frequency of pressure-dependent MA during APAP treatment becomes possible when the totality of MA during such treatment is compared with that occurring during effective conventional CPAP treatment. In earlier investigations we were able to show that, using the Somnosmart, the frequency of MA is no greater than during conventional CPAP treatment. 19 These findings have also been confirmed by other working groups. 15, 16 It may therefore, be concluded that pressure variations during APAP treatment do not induce additional MA on a large scale. Ideally, however, APAP treatment should at any time be capable of applying a treatment pressure that reliably prevents any and all obstructive events, even in situations where the P crit would exceed the treatment pressure during conventional CPAP treatment. In such a case, it is theoretically possible that during treatment with a highly sensitive APAP device, fewer arousals triggered by upper-airways obstruction would occur but that this advantage would be offset by the additional induction of arousals by pressure variations.
With this in mind, we compared the frequency of MA associated with phases of pressure variation with that of MA not associated with phases of pressure variation.
METHODS
Study Population
From the patients referred to our sleep laboratory for the initiation of CPAP therapy, we consecutively recruited 30 adults with mild-to-severe OSA. To confirm the diagnosis, all the patients underwent polysomnography in the sleep laboratory, and a subjective evaluation of daytime sleepiness was obtained using the Epworth Sleepiness Scale (ESS). 23 Only those patients with an apnea/hypopnea index (AHI) of at least 10 per hour, and an ESS score of 10 or more were admitted to the study. Excluded were all patients with a central sleep apnea syndrome or Cheyne-Stokes respiration, patients with contraindications for CPAP treatment; 24 those who had undergone velo-pharyngeal operations previously; those who had used CPAP before; those with clinically manifest nasal obstruction; severe COPD (FEV1<70% predicted), asthma or cardiac disease (NYHA>II), and those who rejected CPAP or refused their consent to participate in the study.
The study protocol was examined and approved by the Ethics Committee of the Friedrich-Alexander University, ErlangenNuremberg.
Positive Airway Pressure Therapy
In this study we used the APAP-device Somnosmart ® (Weinmann, Germany). This APAP-device employs a servo-controlled turbine, and provides positive airway pressures of between 4 and 18 mbar. The treatment pressure is controlled by an algorithm based exclusively on a simplified forced oscillation technique (FOT): A membrane pump generates a sinusoidal signal at a constant frequency of 20 Hz. This membrane pump is connected to the APAP system at the nasal mask via a small tube. The pressure inside the nasal mask is measured via another small tube connected to a piezoresistive transducer inside the APAP device, and the pressure signal is filtered by a 20 Hz band-pass to isolate the forced oscillation components. Changes in the amplitude of this FOT-signal are considered to represent changes in upper airway impedance. The physiologic principles of this simplified FOT and the exact control algorithm of this APAP device have recently been discussed elsewhere. 15, 16, [19] [20] [21] [22] Treatment with the APAP device was carried out with an individually set upper pressure limit. For this purpose, the patient spent one night on the device operated at the manufacturer's settings (treatment pressure 4-18 mbar). On the basis of the course of the pressures recorded on that occasion, the highest pressure that was not exceeded for 95 % of the time (95 % percentile) was calculated and was used as an upper pressure limit for a second APAP treatment on the following night. The maximum speed of pressure increase was set to 0.2 mbar per second, none of the other factory-set values were changed. For the purposes of the present study, the recordings of the patient's second night on the APAP device were evaluated.
Polysomnographies
The diagnostic polysomnographies were performed in our sleep laboratory by trained sleep lab technicians in accordance with the recommendation of the American Thoracic Society and the German Sleep Society. 24, 25 All variables were recorded on a computer (SleepLab, Jaeger and Toennies, Wurzburg, Germany), and included EEG (C4/A1, C3/A2), bilateral EOG, submental and pretibial EMG, nasal airflow measured by oronasal thermistors, snoring detected by microphone, ECG, thoracic and abdominal movements measured by inductive plethysmography, and oxyhemoglobin saturation using a finger oximeter (Microspan 3040G, Jaeger and Toennies, Wurzburg, Germany).
For APAP-titrations and for the APAP study nights, flow was measured by a pneumotachograph (Weinmann, Hamburg, Germany) attached to the nasal mask and APAP was measured continuously at the nasal mask.
Apneas were defined as the absence of oronasal airflow for at least 10 seconds. Hypopneas were defined as a reduction in nasal airflow amplitude to 60% or less of the preceding stable baseline for 10 seconds or longer. The mean number of apneas and hypopnoeas per hour of sleep was calculated as the AHI. Sleep parameters were determined using the criteria of Rechtschaffen and Kales. 26 
Analysis of Pressure Variation and Classification of Microarousals
The MA were defined in accordance with the ASDA criteria 27 Auto-CPAP Therapy for OSA-Fuchs et al SLEEP, Vol. 25, No. 5, 2002 and were classified in two separate analyses.
Analysis A: All 30-second epochs were classified in accordance with the course of the APAP during the respective epoch. Whenever the pressure at the end of the epoch was at least 0.5 mbar higher or lower than at its start, the epoch was classified as a pressure-variation epoch; all other epochs were classified as pressure-variation-free epochs. All MA that occurred during pressure-variation epochs were classified as pressure-dependent; those occurring during pressure-variation-free epochs were classified as pressure-independent MA.
Analysis B: In a separate analysis, the course of the APAP pressure was determined for the 60-second interval prior to each MA. Whenever a change in pressure of at least 0.5 mbar within 30 sec occurred, the following MA was classified as pressuredependent MA. The MA occurring after a pressure increase and those occurring after a pressure decrease were scored separately. All other MA were classified as pressure-independent.
Statistical Analysis
All numbers are expressed as arithmetic means ± standard deviation. Group comparisons were performed using the Wilcoxon-test. The statistical calculations were performed with the aid of SPSS (SPSS Inc., Chicago, Ill., USA version 9.0.1).
For differences between groups a two-tailed p-value of less than 0.05 was considered significant.
RESULTS
All 30 polysomnographies were evaluated as planned. The patient data are shown in Table 1 .
For the 30 nights evaluated, a total of 2535 MA (84.5 ± 45.5 MA/night) occurring in 20,709 epochs (690.3 ± 101.3 epochs per night) were analyzed. The mean arousal index under APAP treatment was 14.5 ± 6.6 MA/h (4.2 ± 32.7).
Analysis A: An average of 607.2 ± 102.4 epochs (87.9% of all epochs) were classified as constant pressure epochs and 83.1 ± 62.8 epochs (12.1% of all epochs) as pressure-dependent epochs. Of these latter, 42.1 ± 28.2 epochs (6.1% of all epochs) were classified as pressure-increase epochs, and 40.9 ± 35.6 epochs (6.0% of all epochs) as pressure-decrease epochs.
Significantly more MA were observed during pressure-dependent epochs (0.30 ± 0.17 MA/epoch) than during constant pressure epochs (0.10 ± 0.05 MA/epoch; p<0.001). The frequency of MA was significantly higher during pressure-increase epochs than during pressure-decrease epochs (0.42 ± 0.24 MA vs. 0.16 ± 0.12 MA/epoch; p<0.001). The frequency of MA expressed as arousal index (frequency of MA/120 epochs) was 12.4 ± 6.5 MA per hour during constant pressure epochs, 50.6 ± 29.2 MA/h during pressure increase, and 19.2 ± 14.7 MA per hour during pressure-decrease epochs (Figure 1) .
The percentage of pressure-dependent MA among the total number of MA varied between 3.0% (2 out of 66 MA) and 61.0% (36 out of 59 MA), with a mean of 26.1% (Figure 2 ).
Analysis B:
Of the total number of 84.5 ± 45.5 MA per night, 69.7 ± 43.5 MA (82.5%) were not preceded by a significant change in pressure. In 9.0 ± 7.8 MA (10.6%), a significant prior increase in pressure occurred, in 5.9 ± 5.0 MA (6.9%), a significant pressure decrease, occurred. The percentage of pressuredependent MA in the total number of MA varied between 2.3% (2 out of 87 MA), and 61.0% (36 out of 59 MA), with a mean of 18.9%.
DISCUSSION
The aim of the present study was to establish whether the automatic variations in pressure occurring during APAP treatment of OSA can induce MA. With this in mind, we wanted to test the hypothesis that pressure variations by the APAP device do not lead to an increase in MA. To this end we compared the frequency of MA during phases of pressure variation with that during phases free of such variation. In summary, however, our results show that neither of the two definitions employed can exclude the possibility that pressure variations might indeed have an impact on the occurrence of MA.
On the basis of our null hypothesis ("automatic pressure variation during APAP therapy induces MA"), we selected criteria for the definition of pressure-associated MA that would presumably result in a very high sensitivity for this parameter. Only when such a sensitive definition is applied could the null hypothesis be rejected in the event that the frequency of pressure-associated MA in phases showing pressure variations was no higher than in phases free of such variations.
We have no reliable information on the temporal relationship between MA and the pressure variations triggering them. In principle, MA might occur either during or following a pressure change. In order to take account of both of these possibilities, we applied two different "definitions" of pressure-associated MA. The first definition was aimed at establishing MA during a pressure variation. For this purpose we employed 30-second epochs according to Rechtschaffen and Kales as the time reference. This relatively long time window of 30 seconds was selected in order to achieve a very high sensitivity for pressure-associated MA. The aim of the second definition was to identify MA preceded by a significant pressure variation. Accordingly, we classified those MA as pressure associated that occurred after a time interval of 60 seconds, during which the treatment pressure varied by at least 0.5 mbar within 30 seconds. Here, too, the time window was chosen to be relatively long, so as to obtain a very high sensitivity for pressure-associated MA.
Not only the temporal relationships between pressure variation and MA are still largely unknown but, we also do not know how large a pressure variation is required to induce an MA. In order to obtain a highly sensitive definition, we classified pressure variations of at least 0.5 mbar within 30 seconds as significant. This is in good accord with our experience gained with manual CPAP titration, where years of working in this field have shown that pressure variations of lower amplitude are very unlikely to induce MA. Overall, therefore, the two definitions would appear well suited to identifying possible pressure-associated MA at a high level of sensitivity. As a consequence, the specificity of the two definitions must be considered to be very low.
On the basis of the results of Analysis A, the frequency of MA during pressure-increase epochs was appreciably higher than in pressure-decrease epochs, and the arousal frequency was lowest during pressure-variation-free epochs. According to Analysis B, in some individuals up to 61% of the MA occurred sequentially to a pressure variation. Therefore, the null hypothesis of our study cannot be rejected-that is, we were unable to exclude the possibility that pressure variations occurring during APAP therapy do indeed trigger MA.
When interpreting this result, however, the methodologic limitations need to be taken into account: the above-mentioned need for a highly sensitive definition of pressure-associated MA necessitates that presumably a large number of MA will be falsely classified as pressure associated. Especially when upper-airway obstruction occurs and the APAP device does not increase pressure quickly enough, a respiratory arousal may be induced but would be misclassified as "pressure-associated" according to Analysis A. Against this background Analysis B seems to be the more clinically relevant of the two analysis. Considering the low specificity of both definitions, it would be wrong to derive quantitative conclusions about the frequency of pressure-associated MA from our data.
The overall arousal index was 14.5±6.6 per hour which is reasonably low when taking into account that the patients were studied in their respective second treatment night without long-term adaptation to CPAP therapy. An observation worthy of particular note is that the percentage of pressure-dependent MA among the total number of MA shows considerable interindividual variation (Figure 2 ). For most patients the proportion of pressure-dependent MA was low and did not result in any significant sleep fragmentation, but in some individuals up to 61% of the total number of MA were classified as pressure dependent. This seems to point to a considerable individual variability of this phenomenon. Unfortunately, within the scope of the present study it was not possible to further characterize subgroups with a large percentage of pressure-dependent arousals.
The control parameters and the algorithms of the various APAP devices available today are largely different. Therefore the results of this study obtained with one specific device cannot be easily transferred to other devices. Nevertheless the basic question of whether automatic pressure changes induce additional microarousals applies to APAP therapy in general and should also be addressed for other devices. In summary we were unable to exclude the possibility that pressure variations occurring during APAP therapy do indeed trigger MA at least in some individuals. We consider that further studies are needed to investigate these relationships more closely. It would, for example, be of interest to determine the effect of controlled pressure changes on the occurrence of MA, with the aim of defining threshold values within which treatment pressure can be varied without triggering MA. Such information might be of considerable value for the optimization of control algorithms for APAP devices.
In the vast majority of patients APAP changes do not induce substantial arousals, and the overall arousal activity during APAP treatment with the Somnosmart ® is no higher than during conventional CPAP therapy. However in some individuals additional MA seem to be induced. Should it prove possible to avoid pressure-associated MA by optimizing the control algorithm of the APAP device, the overall MA activity would be reduced and thus the overall clinical effect of APAP treatment may be improved.
CONCLUSION
The overall frequency of MA was low, and in most individuals the relative number of "pressure-associated MA" was not significant. However the frequency of such pressure-associated MA appears to be highly variable between individuals, and in some individuals a significant proportion of MA may have been induced by pressure variations. Should it prove possible to prevent such pressure-associated MA by further optimizing the regulation of APAP pressure, the overall clinical effect of APAP treatment may be improved.
